# Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease

> **NCT02327221** · PHASE2 · TERMINATED · sponsor: **TxCell** · enrollment: 32 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** Ovasave
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02327221
- **Lead sponsor:** TxCell
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-12
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02327221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02327221, "Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02327221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*